EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune Subtyping of Prostate Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Enables a Multigene Recurrence‐Risk Model

Yu Zhang, Yan Qiu

Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/jcpt/5941762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 13.04.2026. Verfasst von Yu Zhang und 1 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate adenocarcinoma (PRAD) exhibits marked heterogeneity in its immune microenvironment, which influences tumor progression and therapeutic response. However, a comprehensive delineation of immune infiltration patterns and their prognostic relevance in PRAD remains incomplete.

Methods

We analyzed TCGA‐PRAD transcriptomes using ssGSEA, CIBERSORT, ESTIMATE, and complementary deconvolution frameworks (xCell, TIMER, EPIC, and MCPcounter). Immune subtypes were derived by unsupervised clustering of immune‐related gene expression. Differential immune characteristics, clinical associations, and putative immune‐evasion features were examined. Prognostic immune genes were identified via univariate Cox and LASSO‐Cox regression using biochemical recurrence–free survival (BCRFS) as the primary endpoint (PFI/OS exploratory). A multigene risk score was constructed and evaluated by Kaplan–Meier analysis, time‐dependent ROC, calibration, and a nomogram integrating clinical covariates.

Results

Two immune subtypes—Immunity_H and Immunity_L—were identified with distinct tumor microenvironment (TME) features. Immunity_H displayed higher stromal/immune scores, enhanced antigen presentation and interferon signaling, upregulated HLA expression, enrichment of CD8 + T cells, activated memory CD4 + T cells, and M1 macrophages, whereas Immunity_L was characterized by increased M2 macrophages and resting immune populations. A multigene signature stratified patients into high‐ and low‐risk groups with significantly different BCRFS. The risk score correlated negatively with antitumor immune cells (e.g., memory B cells and CD8 + T cells) and positively with immunosuppressive components (e.g., cancer‐associated fibroblasts). Incorporation of the risk score with PSA, Gleason/ISUP grade, and pathologic T/N stage in a nomogram improved individualized recurrence‐risk prediction.

Conclusion

This study delineates the immune heterogeneity of PRAD and proposes a robust immune‐related prognostic model that supports risk stratification and may inform immunotherapeutic decision‐making.

Zitieren

APA

Zhang, Y., & Qiu, Y. (2026). Immune Subtyping of Prostate Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Enables a Multigene Recurrence‐Risk Model. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/5941762

Vancouver

Zhang Y, Qiu Y. Immune Subtyping of Prostate Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Enables a Multigene Recurrence‐Risk Model. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/5941762

BibTeX
@article{Zhang2026,
  author = {Zhang, Yu and Qiu, Yan},
  title = {Immune Subtyping of Prostate Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Enables a Multigene Recurrence‐Risk Model},
  journal = {Journal of Clinical Pharmacy and Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jcpt/5941762}
}
Kostenlos starten →